Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 165

Results For "24"

2047 News Found

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher
News | November 15, 2022

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn


Aurobindo Pharma Q2 FY23 revenue down 3.4%
News | November 14, 2022

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore


Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
News | November 14, 2022

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%

Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers


Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr
News | November 14, 2022

Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr

The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.


Alembic receives USFDA final approval for Cyclophosphamide Capsules
Drug Approval | November 14, 2022

Alembic receives USFDA final approval for Cyclophosphamide Capsules

Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.


Stelis receives recommendation from EMA granting market authorization for Kauliv
Drug Approval | November 14, 2022

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.


Dr. Lucica Ditiu appreciates India's TB elimination response
Policy | November 11, 2022

Dr. Lucica Ditiu appreciates India's TB elimination response

Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi


Lupin Q2 FY2023 revenue remains flat
News | November 10, 2022

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.


Themis Medicare revenue down 15.26%; Profit down 7.76%
News | November 09, 2022

Themis Medicare revenue down 15.26%; Profit down 7.76%

For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%


IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe
News | November 07, 2022

IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe

Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion